Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.66
+1.49 (5.48%)
At close: Jan 22, 2026, 4:00 PM EST
28.10
-0.56 (-1.95%)
After-hours: Jan 22, 2026, 4:33 PM EST
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.88M in the quarter ending September 30, 2025, with 43.69% growth. This brings the company's revenue in the last twelve months to $44.79M, up 36.26% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$44.79M
Revenue Growth
+36.26%
P/S Ratio
34.98
Revenue / Employee
$91,785
Employees
488
Market Cap
1.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAGIO News
- 8 days ago - Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - GlobeNewsWire
- 17 days ago - Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire
- 4 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript - Seeking Alpha
- 4 weeks ago - Agios Pharma Stock: A Buy After FDA Approves Aqvesme - Seeking Alpha
- 4 weeks ago - Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - Invezz
- 4 weeks ago - Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Reuters
- 4 weeks ago - U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia - GlobeNewsWire